UK markets open in 17 minutes
  • NIKKEI 225

    27,772.93
    +305.70 (+1.11%)
     
  • HANG SENG

    24,905.57
    +777.72 (+3.22%)
     
  • CRUDE OIL

    86.90
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    1,840.60
    -2.60 (-0.14%)
     
  • DOW

    35,028.65
    -339.82 (-0.96%)
     
  • BTC-GBP

    30,830.93
    +369.58 (+1.21%)
     
  • CMC Crypto 200

    998.92
    +4.17 (+0.42%)
     
  • ^IXIC

    14,340.25
    -166.64 (-1.15%)
     
  • ^FTAS

    4,273.79
    +10.75 (+0.25%)
     

Nitric Oxide Synthase Inhibitor Pipeline Research Report 2021: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

·4-min read

DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "Nitric Oxide Synthase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Nitric oxide synthase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nitric oxide synthase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nitric oxide synthase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Nitric oxide synthase inhibitors.

Nitric oxide synthase inhibitors Emerging Drugs Chapters

This segment of the Nitric oxide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nitric oxide synthase inhibitors Emerging Drugs

VAS203: Vasopharm BIOTECH

VAS203 is an analogue of the natural co-factor biopterin, which is involved in the generation of nitric oxide by the Nitric Oxide Synthase (NOS) family of enzymes. The mechanism of action of VAS203 is believed to confer selective down regulation of inducible NOS (iNOS) without significantly inhibiting the function of other NOS enzymes.

Vasopharm's ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma.

Nitric oxide synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Nitric oxide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nitric oxide synthase inhibitors

There are approx. 5+ key companies which are developing the therapies for Nitric oxide synthase inhibitors. The companies which have their Nitric oxide synthase inhibitors drug candidates in the most advanced stage, i.e. phase III include Vasopharm BIOTECH.

Key Questions Answered

  • How many companies are developing Nitric oxide synthase inhibitors drugs?

  • How many Nitric oxide synthase inhibitors drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nitric oxide synthase inhibitors?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nitric oxide synthase inhibitors therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Nitric oxide synthase inhibitors and their status?

  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • EyePoint Pharmaceuticals

  • Reata Pharmaceuticals

  • vasopharm BIOTECH

  • Yiviva

  • NeurAxon

  • Neurophyxia

  • SaNOtize Research and Development

  • MediciNova

Key Topics Covered:

Introduction

Executive Summary

Nitric oxide synthase inhibitors: Overview

  • Causes

  • Mechanism of Action

  • Signs and Symptoms

  • Diagnosis

  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type

  • Assessment by Stage and Product Type

  • Assessment by Route of Administration

  • Assessment by Stage and Route of Administration

  • Assessment by Molecule Type

  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

VAS203: Vasopharm BIOTECH

  • Product Description

  • Research and Development

  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

2-iminobiotin: Neurophyxia

  • Product Description

  • Research and Development

  • Product Development Activities

Inactive Products

  • Comparative Analysis

Nitric oxide synthase inhibitors Key Companies

Nitric oxide synthase inhibitors Key Products

Nitric oxide synthase inhibitors- Unmet Needs

Nitric oxide synthase inhibitors- Market Drivers and Barriers

Nitric oxide synthase inhibitors- Future Perspectives and Conclusion

Nitric oxide synthase inhibitors Analyst Views

Nitric oxide synthase inhibitors Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qdg7hb

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005532/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting